Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) reports positive safety data in ten male subjects who received 4000mg of Recce’s R327 product as part of a first-phase clinical trial
  • The subjects are part of the sixth cohort to be intravenously dosed with R327, and the 4000mg dose marks an 80-fold increase from the first cohort
  • Recce says that based on today’s results, it expects an independent safety committee to recommend the commencement of recruitment for cohort seven
  • The company says the study is on track to have all phase-one dosing completed by the second quarter of 2022
  • Shares in Recce Pharmaceuticals are up 22.12 per cent and trading at 69 cents at 2:05 pm AEST

Recce Pharmaceuticals (RCE) has reported positive safety data in ten male subjects who received 4000mg of Recce’s R327 product as part of a first-phase clinical trial.

The subjects were part of the sixth cohort to be intravenously dosed with R327, and the 4000mg dose marks an 80-fold increase from the first cohort, which was dosed with 50mg of R327.

Recce said it observed good safety and tolerability among the 10 subjects in this sixth cohort, meaning the company expects an independent safety committee to recommend the commencement of recruitment for cohort seven based on today’s results.

CEO James Graham said the company was pleased with the data that “strongly” supported the potential of R327 as a new treatment option for patients with sepsis.

“We look forward to continuing to work with the independent safety committee and further evaluating RECCE 327’s safety and tolerability profile in additional cohorts,” Mr Graham said.

The trial is a randomised, placebo-controlled, single-dose study evaluating the safety and pharmacokinetics of R327 in up to ten healthy subjects per dose, across eight sequential dosing cohorts of 50 to 16000 mg.

According to Recce, R327 is the only clinical-stage new class of antibiotics in the world being developed for sepsis — the largest unmet medical need in human health.

The company says the study was on track to have all phase one dosing complete by the second quarter of 2022.

All trials so far have been conducted at Adelaide’s CMAX clinical trial facility.

Shares in Recce Pharmaceuticals were up 22.12 per cent and trading at 69 cents at 2:05 pm AEST.

RCE by the numbers
More From The Market Herald
Wagners (ASX:WGN) - CEO and Managing Director, Cameron Coleman

" Wagners (ASX:WGN) promotes CEO to Managing Director

Building materials company Wagners (ASX:WGN) appoints its current CEO to the board as Managing Director, effective…
The Market Herald Video

" Australasian Metals (ASX:A8G) identifies tantalum mineralisation at Barrow Creek

Australasian Metals (A8G) identifies high-grade tantalum and tin mineralisation at the Barrow Creek Lithium Project in…
The Market Herald Video

" DDH1 (ASX:DDH) launches share-buy back

DDH1 (ASX:DDH) has launched an on-market share buy-back program of up to 10 per cent of…
The Market Herald Video

" Centrex (ASX:CXM) subsidiary signs agreement for beneficiated phosphate trial shipment

Centrex's (ASX:CXM) subsidiary Agriflex has executed an agreement for a trial shipment of beneficiated phosphate with…